Abstract
Objective To describe the prevalence and patterns of antidepressant prescribing in and around pregnancy.
Design Drug utilisation study.
Setting Primary care in the United Kingdom (UK).
Population Women with a pregnancy between 1996 and 2018 in the UK Clinical Practice Research Datalink (CPRD) GOLD Pregnancy Register.
Methods Using primary care prescription records, we identified individuals who had been prescribed antidepressants in and around pregnancy and described changing prevalence of prescribing during pregnancy over time. We defined ‘prevalent’ or ‘incident’ antidepressant use, where ‘prevalent’ users were prescribed antidepressants both before and during pregnancy, and ‘incident’ users were newly prescribed antidepressants during pregnancy, then compared patterns of prescribing between these two groups. We also investigated characteristics associated with antidepressant discontinuation anytime during pregnancy and post-pregnancy prescribing.
Main outcome measures Antidepressant prescribing during pregnancy.
Results A total of 1,033,783 pregnancies were identified: 79,144 (7.7%) were prescribed antidepressants during pregnancy and 15,733 of these (19.9%) were ‘incident’ users. Antidepressant prescribing during pregnancy increased from 3.2% in 1996 to 13.4% in 2018. Most women, both ‘prevalent’ and ‘incident’ users, discontinued antidepressants anytime during pregnancy (54.8% and 59.9%, respectively). The majority of those who discontinued during pregnancy resumed in the 12 months after pregnancy (53.0%). Younger age, previous stillbirth, and higher deprivation were associated with more frequent discontinuation anytime during pregnancy.
Conclusions Antidepressant use during pregnancy appears to be increasing in the UK. Most women discontinued antidepressants at some point before the end of pregnancy, but post-pregnancy resumption of antidepressants was common.
Funding Wellcome Trust 218495/Z/19/Z.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
FZM was supported by a Wellcome Trust PhD studentship (218495/Z/19/Z). GCS was supported by a Medical Research Council (MRC) grant (MR/S009310/1). LB was supported by an NIHR Clinical Lectureship in General Practice (CL-2022-16-001). VNS was supported by an NIHR clinical fellowship (ACF-2016-25-503). PMD and DR were supported by the NIHR Research Bristol Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. FZM, GCS, KEE, PMD and DR are members of the UK MRC Integrative Epidemiology Unit, funded by the MRC (MC_UU_00032/02, MC_UU_00032/04, and MC_UU_00032/6) and the University of Bristol. For Open Access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. The funders of this project had no role in the design or conduct (including analysis or interpretation) of this study, or in the decision to submit this manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
CPRD has ethics approval from the Health Research Authority to support research using anonymised patient data. This particular study was approved by CPRD's Independent Scientific Advisory Committee (ISAC) in 2021 [ISAC number: 21_000362].
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Joint last authors
Data Availability
All data produced in the present work are contained in the manuscript.
